https://lixte.com/
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a clinical-stage pharmaceutical company developing a new class of oncology treatments and cancer therapies...
advancingnoveloncologytreatmentscancer
https://www.uclahealth.org/news/release/nih-grant-awarded-physician-scientist-develop-novel-ways
The National Institutes of Health has awarded Dr. Steven Jonas with a five-year $1.25 million grant through its High-Risk, High-Reward Research Program.
nih grantphysician scientistawardeddevelopnovel
https://www.sciencedaily.com/releases/2007/10/071025125141.htm
What are the cancer drugs of tomorrow and how will they be developed? New targets, such as cell signaling receptors found on cancer tumors, provide tantalizing...
emerging therapiescancertargetshorizonnovel
https://www.prnewswire.com/news-releases/projenx-launches-to-advance-novel-targeted-therapies-for-als-and-other-brain-diseases-301483291.html
/PRNewswire/ -- ProJenX, a New York City-based, clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting...
targeted therapieslaunchesadvancenovelals
https://www.forth.gr/en/news/show/&tid=118&cat=
A network of scientists led by the Foundation of Research & Technology - Hellas (FORTH), Greece, have been awarded a grant from the European Commission Seventh...
framework programmeeuropeanscientistsreceivefunding
https://www.ucsf.edu/news/2021/05/420511/novel-structure-found-tumor-cells-may-open-door-new-kinds-cancer-therapies
UCSF researchers have figured out precisely what receptor tyrosine kinases are, how they form and their role in cancer.
tumor cellsopen doornovelstructurefound
https://www.sciencedaily.com/releases/2020/02/200207141703.htm
Scientists are working to gain a better understand of the growing number of worldwide patented innovations available for gene therapy treatment.
gene therapiesnoveltechniquesminingpatented
https://pubmed.ncbi.nlm.nih.gov/30760019/
Antiplatelet therapies are an essential tool to reduce the risk of developing clinically apparent atherothrombotic disease and are a mainstay in the therapy of...
novelantiplatelettherapiesdiseases
https://www.coherus.com/
Feb 22, 2026 - Coherus Oncology is a commercial-stage company advancing next-generation combination therapies to elevate what’s possible for people living with cancer.
combination therapiesoncologynovelcancer
https://www.mdpi.com/2077-0383/11/11/3002
Neuropathic pain affects more than one million people across the globe. The quality of life of people suffering from neuropathic pain has been considerably...
novel therapiesneuropathic paintreatmentpotential
https://pubmed.ncbi.nlm.nih.gov/33062233/
Individuals with sickle cell disease (SCD) are living further into adulthood in high-resource countries. However, despite increased quantity of life,...
novel therapiescurrentpreventionvasoocclusive
https://www.omicsonline.org/open-access/the-effectiveness-of-physiotherapy-therapies-in-children-and-adolescents-for-back-care-119569.html
-The Effectiveness of Physiotherapy Therapies in Children and Adolescents for Back Care
journalnoveleffectivenessphysiotherapytherapies
https://www.sciencedaily.com/releases/1998/10/981016075643.htm
Neuroscientists at the Yerkes Primate Research Center of Emory University are developing a potential new approach for alleviating the debilitating motor...
brain maynewlyfoundtargetlead
https://www.oncobonetherapeutics.com/
OncoBone Ventures Limited develops novel therapies for cancer patients with bone metastases utilizing a novel concept
oncology therapiesventuresnovel
https://www.mdpi.com/books/reprint/9963-novel-therapies-of-oxidative-stress-induced-age-related-neurodegenerative-diseases
This Special Issue aims to address several important questions regarding the relationship between neurodegenerative disorders and oxidative stress: First, (i)...
novel therapiesoxidative stressneurodegenerative diseasesinducedage
https://www.elanco.com/us/newsroom/press-releases/elanco-announces-changes-to-board-of-directors-signs-research-agreement
Elanco Animal Health Incorporated (NYSE: ELAN) today announced changes to its Board of Directors that will reduce the Board size to 11 directors by the 2025...
elancoannounceschangesboarddirectors
https://www.umassmed.edu/news/news-archives/2014/02/voyager-therapeutics-targets-novel-gene-therapies-to-combat-diseases/
UMMS recognizes Voyager Therapeutics, a gene therapy company founded by four world leaders in the fields of AAV gene therapy, RNA biology and neuroscience.
gene therapiesvoyagertherapeuticstargetsnovel
https://www.biospace.com/abbvie-and-frontier-medicines-establish-global-partnership-to-discover-and-develop-novel-therapies-and-e3-degraders-against-difficult-to-drug-targets
AbbVie (NYSE: ABBV), today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative small molecule...
global partnershipabbviefrontiermedicinesestablish
https://www.pharmaceutical-technology.com/analyst-comment/novel-therapies-niemann-pick/
The Niemann-Pick Type C disease market is expected to grow from $128.35m last year to $188.35m in 2031 across the 3MM.
novel therapiesniemann pickentrancedrivetype